ASCO GI Highlights

A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.

Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.

Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.

Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.

Amit Mahipal, MD, presented results from a real-world data study examining the rates of molecular alterations detected using circulating tumor DNA (ctDNA) for patients receiving ivosidenib following circulating tumor ctDNA-detected IDH1 mutations.

Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.

Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.

FIRST-308 is an open-label, phase 2, randomized, global, multicenter study that will evaluate the efficacy and safety of oral tinengotinib versus physician’s choice in patients with fibroblast growth factor receptor (FGFR)-altered, chemotherapy- and FGFR inhibitor-refractory/relapsed cholangiocarcinoma—this article will review the study’s eligibility criteria, primary endpoints, and more.

Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.

The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.